

Tina-quant Soluble Transferrin Receptor II**Order information**

REF	CONTENT	Analyzer(s) on which cobas c pack(s) can be used
08870217190	Tina-quant Soluble Transferrin Receptor II(100 tests)	System-ID 2108 001 cobas c 503
Materials required (but not provided):		
08753776190	Calibrator sTfR II (3 x 1 mL)	Codes 20697
08278202190	ControlSet sTfR II	
	Level I (3 x 1 mL)	Level I Code 20153
	Level II (3 x 1 mL)	Level II Code 20154
08063494190	Diluent NaCl 9 % (123 mL)	System-ID 2906 001

English**System information****STFR2:** ACN 21080**Intended use**

In vitro test for the quantitative determination of soluble transferrin receptor (sTfR) in human serum and plasma on **cobas c** systems.

Summary^{1,2,3,4,5,6,7}

The transferrin receptor is an integral membrane glycoprotein having a molecular weight of 190 kilodalton (kDa). It consists of two identical subunits linked by disulfide bridges. Each of the monomers has an 85 kDa C-terminal component which can bind an iron-laden transferrin molecule. Proteolysis leads to the soluble form of the transferrin receptor (sTfR). In plasma, the soluble transferrin receptor is present in the form of a complex with transferrin having a molecular weight of approximately 320 kD. The serum concentration of sTfR is directly proportional to the concentration of the receptor on the membrane.

The uptake of iron by the body's cells is controlled by expression of the transferrin receptor (TfR). If the intracellular iron stores are exhausted - corresponding to a ferritin concentration of less than 12 µg/L - then more TfR is expressed. The affinity of the transferrin receptor to transferrin depends on the latter's loading state. As 80-95 % of the transferrin receptor molecules are localized on erythropoietic cells, the TfR concentration (and hence also the sTfR concentration) reflects the iron requirement of these cells. When iron deficiency exists, the sTfR concentration in serum rises even before the hemoglobin concentration is significantly depressed. The sTfR concentration can therefore describe the functional iron status while ferritin reflects the iron storage status. A precise assessment of the iron status can be obtained by determining the sTfR index (= sTfR concentration/log ferritin concentration).

As - in contrast to ferritin - the concentration of sTfR is not affected by acute-phase reactions, acute liver function disorders or malignant tumors, it is possible to differentiate between anemia of chronic disease (ACD) and iron deficiency anemia (IDA). Elevated sTfR values are also found in polycythemia, hemolytic anemia, thalassemia, hereditary spherocytosis, sickle cell anemia, megaloblastic anemia, myelodysplastic syndrome and vitamin B₁₂ deficiency. Elevated sTfR concentrations occur during pregnancy when there is a deficiency of functional iron.

Parameter	Change	IDA	ACD	IDA + ACD	
Ferritin	iron stores	↓	↑	—	or ↑
TIBC/TRSF	iron status	↑	↓	↑	or —
Serum iron	iron status	↓	↓	↓	
sTfR	functional iron deficiency	↑	—	↑	

↓ decreased, ↑ increased, — unchanged

Test principle⁸

Particle enhanced immunoturbidimetric assay.

Human soluble transferrin receptor agglutinates with latex particles coated with anti-soluble transferrin receptor antibodies. The precipitate is determined photometrically.

Reagents - working solutions

R1 TRIS buffer: with bovine serum albumin; preservatives

R3 Latex particles coated with monoclonal anti-human sTfR antibodies (mouse) in glycine buffer; preservative

R1 is in position B and R3 is in position C.

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:

**Warning**

H317 May cause an allergic skin reaction.

H412 Harmful to aquatic life with long lasting effects.

Prevention:

P261 Avoid breathing dust/fume/gas/mist/vapours/spray.

P273 Avoid release to the environment.

P280 Wear protective gloves.

Response:

P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

Disposal:

P501 Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

Reagent handling

Ready for use

Carefully invert reagent container several times prior to use to ensure that the reagent components are mixed.

Storage and stability

Shelf life at 2-8 °C:

See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 26 weeks

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.
Serum.

Plasma: Heparin (Li-, Na-, NH₄⁺-) plasma

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

See the limitations and interferences section for details about possible sample interferences.

Stability:	6 days at 15-25 °C
	15 days at 2-8 °C
	13 weeks at -20 °C (±5 °C) (freeze only once)

Sample stability claims were established by experimental data by the manufacturer or based on reference literature and only for the temperatures/time frames as stated in the method sheet. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine specific stability criteria for its laboratory.

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- See "Order information" section
- General laboratory equipment

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Application for serum and plasma**Test definition**

Reporting time	10 min		
Wavelength (sub/main)	800/570 nm		
Reagent pipetting		Diluent (H ₂ O)	
R1	70 µL	-	
R3	28 µL	-	
Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)
Normal	1.4 µL	-	-
Decreased	1.4 µL	20 µL	60 µL
Increased	1.4 µL	-	-

For further information about the assay test definitions refer to the application parameters setting screen of the corresponding analyzer and assay.

Calibration

Calibrators	S1: H ₂ O S2-S6: Calibrator sTfR II
Calibration mode	Non-linear

Calibration frequency**Full calibration**

- after reagent lot change
- after 12 weeks on-board the analyzer
- after 6 months when using a single reagent lot
- as required following quality control procedures

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against an in-house reference preparation.

Quality control

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

cobas c systems automatically calculate the analyte concentration of each sample in the unit mg/L (nmol/L, mg/dL).

Conversion factors:	mg/L x 11.8 = nmol/L ^{9,a)}
	mg/L x 0.1 = mg/dL

a) Based on a molecular mass of 85 kDa for circulating transferrin receptor.

Limitations – interference

Criterion: Recovery within ± 0.2 mg/L (2.36 nmol/L) of initial values of samples ≤ 2 mg/L (23.6 nmol/L) and within ± 10 % for samples > 2 mg/L.

Icterus:¹⁰ No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 µmol/L or 60 mg/dL).

Hemolysis:¹⁰ No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 622 µmol/L or 1000 mg/dL).

Lipemia (Intralipid):¹⁰ No significant interference up to an L index of 2000. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Rheumatoid factors: No significant interference from rheumatoid factors up to a concentration of 1200 IU/mL.

High dose hook-effect: No false result occurs up to an sTfR concentration of 80 mg/L (944 nmol/L).

The antibodies are specific for sTfR. There is no cross-reactivity with diferrotransferrin, apotransferrin or ferritin under the assay conditions.

Drugs: No interference was found at therapeutic concentrations using common drug panels.^{11,12}

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.¹³

In very rare cases, patient samples may contain particle agglutinating proteins (e.g. heterophilic antibodies or antibodies due to abnormal immunoglobulin synthesis, such as gammopathies like MGUS* or Waldenström's macroglobulinemia) which may lead to incorrect low or high results with this assay. Correct results cannot be obtained by sample dilution and these samples should be analyzed by an alternative method.

*Monoclonal Gammopathy of unknown significance

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on **cobas c** systems. All special wash programming necessary for avoiding carry-over is available via the **cobas** link. The latest version of the carry-over evasion list can be found with the NaOHD/SMS/SCCS Method Sheet for information. For further instructions refer to the operator's manual.

Limits and ranges**Measuring range**

0.50-20.0 mg/L (5.9-236 nmol/L)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:4 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 4.

Lower limits of measurement*Limit of Blank, Limit of Detection and Limit of Quantitation*

Limit of Blank = 0.25 mg/L (2.95 nmol/L)

Limit of Detection = 0.40 mg/L (4.72 nmol/L)

Limit of Quantitation = 0.50 mg/L (5.90 nmol/L)

The Limit of Blank and Limit of Detection were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95th percentile value from $n \geq 60$ measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with a total error of 20 %. It has been determined using low concentration sTfR samples.

Expected values

The values shown below were performed on samples from an apparently healthy population, using the Tina-quant Soluble Transferrin Receptor II assay (STFR2). The calculation is based on 165 sera (101 men, 64 women). The age range was between 22 and 83 years. The analysis of the data with the 2.5 % and the 97.5 % percentile gave a soluble transferrin receptor (sTfR) range from 1.71 mg/L (20.2 nmol/L) to 4.13 mg/L (48.7 nmol/L).

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP5-A3 requirements with repeatability ($n = 84$) and intermediate precision (2 aliquots per run, 2 runs per day, 21 days)

The following results were obtained:

Repeatability	Mean	SD	CV
	mg/L	mg/L	%
Control Set sTfR II L 1	2.36	0.0275	1.2
Control Set sTfR II L 2	7.03	0.0407	0.6
Human serum 1	1.20	0.0289	2.4
Human serum 2	1.95	0.0476	2.4
Human serum 3	5.32	0.0316	0.6
Human serum 4	9.78	0.0511	0.5
Human serum 5	17.4	0.0748	0.4
Intermediate precision	Mean	SD	CV
	mg/L	mg/L	%
Control Set sTfR II L 1	2.36	0.0290	1.2

Control Set sTfR II L 2	7.03	0.0525	0.7
Human serum 1	1.20	0.0335	2.8
Human serum 2	1.95	0.0508	2.6
Human serum 3	5.32	0.0454	0.9
Human serum 4	9.78	0.0716	0.7
Human serum 5	17.4	0.117	0.7

Method comparison

sTfR values for human serum and plasma samples obtained on a **cobas c 503** analyzer (y) were compared with those determined using the corresponding reagent on a **cobas c 501** analyzer(x).

Sample size (n) = 66

Passing/Bablok ¹⁴	Linear regression
$y = 1.028x - 0.0786 \text{ mg/L}$	$y = 1.030x - 0.0809 \text{ mg/L}$
$r = 0.983$	$r = 1.000$

The sample concentrations were between 0.560 and 18.6 mg/L.

References

- Wick M, Pinggera W, Lehmann P, eds. Iron Metabolism, Diagnosis and Therapy of Anemias. 4th ed. Vienna/New York: Springer Verlag 1999.
- Ferguson BJ, Skikne BS, Simpson KM, et al. Serum transferrin receptor distinguishes the anemia of chronic diseases from iron deficiency anemia. J Lab Clin Med 1992;19:385-390.
- Baynes RD, Skikne BS, Cook JD. Circulating transferrin receptors and assessment of iron status. J Nutr Biochem 1994;5:322-330.
- Kuiper-Kramer EPA, Huisman CMS, van Raan J, et al. Analytical and clinical implications of soluble transferrin receptors. Eur J Clin Chem Clin Biochem 1996;34:645-649.
- Baynes RD. Assessment of iron status. Clin Biochem 1996;29:209-215.
- Punnonen K, Irijala K, Rajamäki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997;89:1052-1057.
- Suominen P, Punnonen K, Rajamäki A, et al. Serum transferrin receptor and transferrin receptor-ferritin index identify healthy subjects with subclinical iron deficits. Blood 1998;92:2934-2939.
- Haeckel R, ed. Evaluation methods in laboratory medicine. VCH Verlagsgesellschaft, Weinheim 1993.
- Cook JD, Skikne BS, Baynes RD. Serum transferrin receptor. Annu Rev Med 1993;44:63-74.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

STFR2

Tina-quant Soluble Transferrin Receptor II



Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see dialog.roche.com for definition of symbols used):

	Contents of kit
	Volume for reconstitution
	Global Trade Item Number



COBAS, COBAS C and TINA-QUANT are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2021, Roche Diagnostics



 Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com
 +800 5505 6606

